GB0906159D0 - Drug combination for the treatment of proteostatic diseases - Google Patents

Drug combination for the treatment of proteostatic diseases

Info

Publication number
GB0906159D0
GB0906159D0 GBGB0906159.9A GB0906159A GB0906159D0 GB 0906159 D0 GB0906159 D0 GB 0906159D0 GB 0906159 A GB0906159 A GB 0906159A GB 0906159 D0 GB0906159 D0 GB 0906159D0
Authority
GB
United Kingdom
Prior art keywords
treatment
drug combination
proteostatic
diseases
proteostatic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0906159.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Summit Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp PLC filed Critical Summit Corp PLC
Priority to GBGB0906159.9A priority Critical patent/GB0906159D0/en
Publication of GB0906159D0 publication Critical patent/GB0906159D0/en
Priority to PCT/GB2010/000710 priority patent/WO2010116141A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
GBGB0906159.9A 2009-04-09 2009-04-09 Drug combination for the treatment of proteostatic diseases Ceased GB0906159D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0906159.9A GB0906159D0 (en) 2009-04-09 2009-04-09 Drug combination for the treatment of proteostatic diseases
PCT/GB2010/000710 WO2010116141A2 (en) 2009-04-09 2010-04-07 Drug combination for the treatment of proteostatic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0906159.9A GB0906159D0 (en) 2009-04-09 2009-04-09 Drug combination for the treatment of proteostatic diseases

Publications (1)

Publication Number Publication Date
GB0906159D0 true GB0906159D0 (en) 2009-05-20

Family

ID=40750361

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0906159.9A Ceased GB0906159D0 (en) 2009-04-09 2009-04-09 Drug combination for the treatment of proteostatic diseases

Country Status (2)

Country Link
GB (1) GB0906159D0 (en)
WO (1) WO2010116141A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155936A1 (en) 2008-06-26 2009-12-30 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
JP2013544263A (en) 2010-11-30 2013-12-12 オルファザイム エーピーエス Method for increasing intracellular activity of Hsp70
WO2012149268A1 (en) 2011-04-29 2012-11-01 Selecta Biociences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
US10357483B2 (en) 2013-05-03 2019-07-23 Selecta Biosciences, Inc. Methods comprising dosing combinations for reducing undesired humoral immune responses
AU2015311707B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
CN109069496A (en) 2016-04-29 2018-12-21 奥菲泽米有限公司 For treating the arimoclomol of glucocerebrosidase related disease
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
MX2023005954A (en) 2020-11-19 2023-09-04 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
KR20080033242A (en) * 2005-06-08 2008-04-16 아미쿠스 세라퓨틱스, 인코포레이티드 Methods of treating CNS disease associated with mutations in genes encoding lysosomal enzymes
ATE555788T1 (en) * 2006-06-23 2012-05-15 Amicus Therapeutics Inc METHOD FOR TREATING NEUROLOGICAL DISEASES BY ENHANCEMENT OF BETA-GLUCOCEREBROSIDASE ACTIVITY
WO2008054947A2 (en) * 2006-10-02 2008-05-08 The Brigham And Women's Hospital, Inc. Structure of acid beta-glucosidase and methods for identifying therapeutic agents
MX2009011473A (en) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones.
WO2009049421A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
WO2009066069A1 (en) * 2007-11-21 2009-05-28 Summit Corporation Plc Treatment of protein folding disorders
US20110237538A1 (en) * 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases

Also Published As

Publication number Publication date
WO2010116141A2 (en) 2010-10-14
WO2010116141A3 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
IL259475A (en) Combination therapy for the treatment of diabetes
IL219073A (en) Pharmaceutical combination for treatment of cancer
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
ZA200906210B (en) 3-Imidazolyl-Indoles for the treatment of proliferative diseases
IL216509A0 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
ZA201301601B (en) Treatment of diseases
EP2166837A4 (en) Drug combination for the treatment of skin disorders
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
ZA201208646B (en) Pharmaceutical combination for the treatment of pain
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
GB0908193D0 (en) Treatment of disease state
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
IL213606A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflamatory skin diseases
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
IL216717A (en) Use of benzydamine in the manufacture of a medicament for the treatment of p40-dependent diseases
GB0901727D0 (en) The treatment of ophthalmic diseases
GB0801511D0 (en) The treatment of ophthalmic diseases
GB0908666D0 (en) Treatment of proteostatic disease
GB0920651D0 (en) Molecular methods for the treatment of disease
GB0819543D0 (en) Treatment of proteostatic disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)